<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Reich, Kristian</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Apremilast Was Associated with an Acceptable Safety Profile in ESTEEM Trials</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-7</style></pages><abstract><style  face="normal" font="default" size="100%">Two phase 3 randomized controlled trials were performed to evaluate the safety and efficacy of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis. This article discusses the safety analysis from the pooled data of the ESTEEM 1 [NCT01194219] and ESTEEM 2 trials [NCT01232283].</style></abstract><number><style face="normal" font="default" size="100%">37</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>